ERBB2 and non-small cell lung carcinoma: Researchers have developed anti-HER2 CAR-T cells with 4-1BB and CD3ζ signaling domains, and initiated a phase I/II study to demonstrate its safety and feasibility in treating HER2-positive solid tumors, including NSCLC (NCT01935843).